Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort-Reference-Cited by-同舟云学术

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Published:2023-08 Issue: Volume:189 Page:112935
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Grinda Thomas,Antoine Alison,Jacot William,Cottu Paul-Henri,de la Motte Rouge Thibault,Frenel Jean-Sébastien,Mailliez Audrey,Dalenc Florence,Goncalves Anthony,Clatot Florian,Mouret Reynier Marie-Ange,Levy Christelle,Ferrero Jean-Marc,Desmoulins Isabelle,Uwer Lionel,Petit Thierry,Jouannaud Christelle,Arnedos Monica,Chevrot Michaël,Courtinard Coralie,Tredan Olivier,Brain Etienne,Pérol David,Pistilli Barbara,Delaloge Suzette

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs;Bianchini;Nat Rev Clin Oncol,2022

3. Pattern of metastatic spread in triple-negative breast cancer;Dent;Breast Cancer Res Treat,2009

4. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016;Deluche;Eur J Cancer Oxf Engl 1990,2020

5. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort;Grinda;ESMO Open,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe;European Journal of Cancer;2024-08

2. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer;Annals of Oncology;2024-07

3. Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes;Annals of Oncology;2024-07

4. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer;Cancer Treatment Reviews;2024-07

5. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study;BMC Medicine;2024-06-18